Schistosoma mansoni: analysis of the humoral and cellular basis of resistance in guinea-pigs vaccinated with radiation-attenuated cercariae

Schistosoma mansoni: evidence that site-dependent host responses determine when and where vaccine immunity is expressed in different rodent species

Laboratory rodents vaccinated with highly irradiated cercariae of Schistosoma mansoni develop significant levels of specific acquired resistance yet effect challenge elimination in different organs. Mice and guinea-pigs are at opposite ends of the spectrum in this respect since, in our hands, vaccinated mice kill challenge parasites in the skin whereas vaccinated guinea-pigs kill challenge parasites predominantly in the liver. To determine whether this phenomenon is host-dependent (site) or parasite-dependent (stage), we have transferred worms harvested from mice or guinea-pigs into vaccinated recipient guinea-pigs. The results show that mouse-derived 5-day lung worms and 9-day liver worms that are essentially refractory to vaccine resistance in mice are indeed susceptible to vaccine resistance in guinea-pigs. Identical levels of susceptibility were recorded for lung-stage larvae introduced via the foot vein so as to experience lung and liver mechanisms, or via the mesenteric vein to bypass the lung, thereby confirming that vaccine resistance in guinea-pigs operates in the liver. Mouse worms and guinea-pig worms exhibited equivalent levels of susceptibility at all stages of development. Thirteen-day-old larvae from either donor species were on the border-line of vulnerability, while 20-day-old worms were totally refractory to vaccine immunity in guinea-pigs. These data show that vaccine immunity in different rodent species is a site-dependent, rather than a stage-dependent phenomenon. There is, however, an upper age limit of schistosome vulnerability which is common to worms harvested from different donor species.

Evidence for enhancement of IgG1 subclass expression in mice polyvaccinated with radiation-attenuated cercariae of Schistosoma mansoni and the role of this isotype in serum-transferred immunity

Serum or immunoglobulin fractions of serum from CBA/Ca mice vaccinated three or four times with radiation-attenuated cercariae of Schistosoma mansoni have been investigated for their capacity to confer protection upon naive mice. The data confirm that around 35% protection can be transferred with polyvaccine mouse serum administered in 0.5-ml aliquots 1 h before challenge (intravenously) and 24 h post-challenge (intraperitoneally). We show in addition, however, that polyvaccine serum is also protective when injected into the skin site of challenge as a single 0.05-ml aliquot. In contrast, lymphocytes obtained from the donors of protective serum conferred only 13% protection upon recipient mice. The passive cutaneous anaphylaxis assay showed that IgG1 is incremented by polyvaccination, while passive transfer experiments revealed that of the different isotypes fractionated from whole protective serum, only IgG1 has the capacity to protect naive recipients against challenge. The resistance transferred by IgG1 represents more than 60% of that obtained with whole serum and can be achieved using either the intravenous/intraperitoneal or the subcutaneous administration regimen. Recipients of serum given via the subcutaneous route exhibit cutaneous inflammatory focal reactions which comprise 20% eosinophils and 80% mononuclear cells; these foci entrap challenge larvae. The importance of IgG1 subclass expression to the success of serum-transferred resistance is discussed.